Our report of IVUS guided stenting of HeartMate 3 extrinsic outflow graft obstruction (EOGO) in @JACCJournals Interventions. How often are you seeing these cases? Are you screening all HM3 patients with CTAs? How are you treating these patients? authors.elsevier.com/a/1kJtd…
Great technique to bail-out lost wire position in the LV during balloon-expandable TAVR using a 4-8 mm EN-snare through the delivery system. Nice! @ryankaple@CraigBasman
A Microsnare Technique for Transcatheter Heart Valve Recrossing After Inadvertent Wire Withdrawal From Left Ventricle | JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.jcin.…
Join us for our Advances in Cardiovascular Symposium on Wednesday, Sept 25, from 5:00 - 8:00 pm. Registration is free (in person or virtual). We will review ablation for AFib, updates in CTO interventions, and percutaneous tricsupid valve interventions lnkd.in/eQqV7mDU
A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park@GreggWStone@JungMinAhn5@DFCapodanno@djc795@TheLancet
Further details:
doi.org/10.1016/S0140-6736(2…
My conclusion is:
TAVI (whoppingly) superior to SAVR at 1 year in this trial where the heart team decided on type of transcatheter heart valve for their patient.
@djc795@vonBardelebenRS @MattiAdam_MD @PhilippLurz
Presented today at #ACC24:
A randomized trial that enrolled patients with severe aortic stenosis at low or intermediate surgical risk showed that TAVI was noninferior to SAVR at 1 year. Read the full DEDICATE-DZHK6 trial results: nej.md/3TLx8MT
ALT Kaplan–Meier estimate (stratified according to the criteria of the Society of Thoracic Surgeons) of the risk of the primary outcome
ALT Kaplan–Meier estimate of the risk of death from any cause
Structural Case of the Week;
35 y/o M with rheumatic MS (Mean MV gradient 15) for PMBV.
Intracardiac echo guidance with 9Fr Philips 3D ICE.
MVA 0.9 -> 2.2. MV gradient 15mmHg-> 3mmHg
@HMHNewJersey@Philips@ryankaple#Structuralheart#TAVR#Mitral
The tricuspid valve, often referred to as the forgotten valve, has generated intense interest because of converging factors that make diagnosis and management of tricuspid regurgitation uniquely challenging.
Read the Review Article: nej.md/42IBvf1 1/15
#cardiology
For patients with severe tricuspid regurgitation, transcatheter edge-to-edge repair (TEER) has emerged as a safe and potentially effective treatment option.
Read the full TRILUMINATE Pivotal trial Research Summary: nej.md/3kwJVFt